Patent ID: 9724399
Date: 2017-08-08
CPC Classifications: A61K,A61P,C07K,G01N

Claim:
1. A method of reducing aggregates of α-synuclein in a subject having a disease selected from the group consisting of Lewy Body Disorders (LBDs), Parkinson's Disease (PD), Parkinson's Disease with Dementia (PDD), Dementia with Lewy Bodies (DLB), Multiple System Atrophy (MSA), and Neurodegeneration with Brain Iron Accumulation type I (NBIA Type I), comprising administering, to a subject in need thereof, a compound comprising a peptide having the amino acid sequence of XDQPVLPD (SEQ ID NO: 59) wherein X is cysteine or not present, wherein the compound induces an antibody that has specific binding capacity for an epitope of alpha-synuclein comprising the amino acid sequence DMPVDPDN (SEQ ID NO: 1), and wherein the antibody has no reactivity to beta-synuclein or lower immune reactivity to beta-synuclein compared to alpha synuclein epitope comprising DMPVDPDN (SEQ ID NO:1).